Sirtori, Cesare R.

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

Cuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., et al. (2013) · The Lancet

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 744

An ω-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia

Calabresi, L., Villa, B., Canavesi, M., Sirtori, C. R., James, R. W., Bernini, F., & Franceschini, G. (2004) · Metabolism

Fatty Acid Research and HealthParaoxonase enzyme and polymorphisms

Cited by 132

Functional Lecithin: Cholesterol Acyltransferase Is Not Required for Efficient Atheroprotection in Humans

Calabresi, L., Baldassarre, D., Castelnuovo, S., Conca, P., Bocchi, L., Candini, C., Frigerio, B., Amato, M., Sirtori, C. R., Alessandrini, P., et al. (2009) · Circulation

Cholesterol and Lipid MetabolismLipid metabolism and disorders

Cited by 130

One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance

Sirtori, C. R., Crepaldi, G., Manzato, E., Mancini, M., Rivellese, A., Paoletti, R., Pazzucconi, F., Pamparana, F., & Stragliotto, E. (1998) · Atherosclerosis

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 95

Lipid Lowering Drugs: Present Status and Future Developments

Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 73

Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients

Franceschini, G., Calabresi, L., Colombo, C., Favari, E., Bernini, F., & Sirtori, C. R. (2007) · Atherosclerosis

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 66

Non-pharmacological control of plasma cholesterol levels

Poli, A., Marangoni, F., Paoletti, R., Mannarino, E., Lupattelli, G., Notarbartolo, A., Aureli, P., Bernini, F., Cicero, A., Gaddi, A., et al. (2008) · Nutrition, Metabolism and Cardiovascular Diseases

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 63

Depression and cardiovascular risk-association among Beck depression inventory, PCSK9 levels and insulin resistance

Macchi, C., Favero, C., Ceresa, A., Vigna, L., Conti, D. M., Pesatori, A. C., Racagni, G., Corsini, A., Ferri, N., Sirtori, C. R., et al. (2020) · Cardiovascular Diabetology

Diabetes, Cardiovascular Risks, and LipoproteinsCardiac Health and Mental Health

Cited by 51

Double-blind study of the addition of high-protein soya milk v. cows' milk to the diet of patients with severe hypercholesterolaemia and resistance to or intolerance of statins

Sirtori, C. R., Pazzucconi, F., Colombo, L., Battistin, P., Bondioli, A., & Descheemaeker, K. (1999) · British Journal Of Nutrition

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 46

Impact of PPAR-Alpha Polymorphisms—The Case of Metabolic Disorders and Atherosclerosis

Ruscica, M., Busnelli, M., Runfola, E., Corsini, A., & Sirtori, C. R. (2019) · International Journal of Molecular Sciences

Peroxisome Proliferator-Activated ReceptorsParaoxonase enzyme and polymorphisms

Cited by 33